Source:http://linkedlifedata.com/resource/pubmed/id/18031740
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2007-12-10
|
| pubmed:abstractText |
Rifampicin, an antibacterial drug widely used in the treatment of tuberculosis and leprosy, has recently been reported to have anti-oxidative and anti-apoptotic effects. However, its anti-angiogenic effect has not been investigated. We examined its anti-angiogenic effect on tube formation and proliferation by human umbilical vein endothelial cells (HUVECs) in vitro and on retinal neovascularization in a murine oxygen-induced retinopathy model in vivo. In addition, we explored the potential mechanisms for its anti-angiogenic effect. Rifampicin significantly suppressed HUVEC tube formation and proliferation, and its effects appeared to be mediated at least in part through inhibition of extracellular signal-regulated kinase (ERK) 1/2 phosphorylation. Retinal neovasuclarization was induced in neonatal mice by returning the retina to normoxia (21% O2) after exposure to hyperoxia (75% O2) from postnatal day 7 (P7) to P12. Rifampicin was given subcutaneously at 20mg/kg once a day from immediately after hyperoxia (P12) to P16. At P17, flat-mounted retinas were prepared and evaluated for pathological and physiological angiogenesis. Rifampicin significantly suppressed retinal neovascularization (versus vehicle treatment), but revascularization of the capillary-free area did not differ between vehicle and rifampicin treatment. Rifampicin has anti-angiogenic effects in vitro and in vivo, and may be useful as an anti-angiogenic agent in the treatment of retinal neovascularization diseases.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Oxygen,
http://linkedlifedata.com/resource/pubmed/chemical/Rifampin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0014-4835
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
86
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
131-7
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:18031740-Angiogenesis Inhibitors,
pubmed-meshheading:18031740-Animals,
pubmed-meshheading:18031740-Body Weight,
pubmed-meshheading:18031740-Cell Proliferation,
pubmed-meshheading:18031740-Cells, Cultured,
pubmed-meshheading:18031740-Disease Models, Animal,
pubmed-meshheading:18031740-Dose-Response Relationship, Drug,
pubmed-meshheading:18031740-Drug Evaluation, Preclinical,
pubmed-meshheading:18031740-Endothelium, Vascular,
pubmed-meshheading:18031740-Humans,
pubmed-meshheading:18031740-Mice,
pubmed-meshheading:18031740-Mice, Inbred C57BL,
pubmed-meshheading:18031740-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:18031740-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:18031740-Oxygen,
pubmed-meshheading:18031740-Phosphorylation,
pubmed-meshheading:18031740-Retinal Neovascularization,
pubmed-meshheading:18031740-Rifampin
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Rifampicin inhibits the retinal neovascularization in vitro and in vivo.
|
| pubmed:affiliation |
Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, 502-8585 Gifu, Japan.
|
| pubmed:publicationType |
Journal Article
|